XML 25 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Financial Instruments
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Financial Instruments
Financial Instruments
Assets and Liabilities Measured at Fair Value on a Recurring Basis.
The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at June 30, 2016 and December 31, 2015.
 
Fair Value as of June 30, 2016
(in thousands)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Corporate debt securities
$

 
$
2,259

 
$

 
$
2,259

  Equity securities

 
458

 

 
458

  Total
$

 
$
2,717

 
$

 
$
2,717

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Acquisition related contingent consideration
$

 
$

 
$
145

 
$
145

 
 
 
 
 
 
 
 
 
Fair Value as of December 31, 2015
(in thousands)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Corporate debt securities
$

 
$
3,227

 
$

 
$
3,227

  Equity securities

 
491

 

 
491

  Total
$

 
$
3,718

 
$

 
$
3,718

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Acquisition related contingent consideration
$

 
$

 
$
175

 
$
175

 
 
 
 
 
 
 
 

The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the six months ended June 30, 2016.
Equity securities consist of shares of Perma-Fix Medical S.A. ("Perma-Fix Medical") a publicly traded company listed on the NewConnect market of the Warsaw Stock Exchange. Fair value of the Perma-Fix Medical investment is based on the closing price observed on June 30, 2016.
The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014 and acquisition of MD Office on March 5, 2015 (See Note 3).  We reassess the fair value of the contingent consideration to be settled in cash related to our acquisitions of Telerhythmics and MD Office on a quarterly basis using the income approach, which is a Level 3 measurement. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones.
Changes in estimated fair value of contingent consideration liabilities (Level 3 measurement) from December 31, 2015 to June 30, 2016 are as follows (in thousands):
 
 
Telerhythmics Contingent Consideration
 
MD Office Solutions Contingent Consideration
 
Total Contingent Consideration
Balance at December 31, 2015
 
$
22

 
$
153

 
$
175

Contingent consideration payments
 

 
(27
)
 
(27
)
Change in estimated fair value
 
(17
)
 
14

 
(3
)
Balance at June 30, 2016
 
$
5

 
$
140

 
$
145


The fair values of the Company's term loans and revolving credit facility approximate carrying value due to the variable rate nature of these instruments.
Securities Available-for-Sale
Securities available-for-sale primarily consist of investment grade corporate debt securities. In addition, we own shares of common stock issued by Perma-Fix Medical, a publicly traded company on the NewConnect market of the Warsaw Stock Exchange. We classify all debt securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. The Perma-Fix Medical equity securities are classified as an other asset (non-current), as the investment is strategic in nature and our current intent is to hold the investment over a several year period. Securities available-for-sale are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income. The realized gains and losses on these sales were minimal for the three and six months ended June 30, 2016 and 2015.
The following table sets forth the composition of securities available-for-sale as of June 30, 2016 and December 31, 2015.
 
Maturity in
Years
 
Cost
 
Unrealized
 
Fair Value
As of June 30, 2016 (in thousands)
Gains
 
Losses
 
Corporate debt securities
Less than 1 year
 
$
2,259

 
$

 
$

 
$
2,259

Corporate debt securities
1-3 years
 

 

 

 

Equity securities
-
 
721

 

 
(263
)
 
458

 
 
 
$
2,980

 
$

 
$
(263
)
 
$
2,717

 
 
 
 
 
 
 
 
 
 
 
Maturity in
Years
 
Cost
 
Unrealized
 
Fair Value
As of December 31, 2015 (in thousands)
Gains
 
Losses
 
Corporate debt securities
Less than 1 year
 
$
2,311

 
$

 
$
(5
)
 
$
2,306

Corporate debt securities
1-3 years
 
926

 

 
(5
)
 
921

Equity securities
-
 
721

 

 
(230
)
 
491

 
 
 
$
3,958

 
$

 
$
(240
)
 
$
3,718